Sean P. Nolan
Sean P. Nolan is a former chief executive of AveXis, the company behind the development of Zolgensma, a gene therapy for spinal muscular atrophy (SMA). He played a pivotal role in taking the company public and navigating the commercialization of the drug amidst rising scrutiny over drug pricing.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United States:
Sean P. Nolan was appointed as the CEO of AveXis after John Carbona and oversaw the company's IPO.
5